Publication
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugSorafenibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneARAFcivic_curation1.00
- geneRAF1civic_curation1.00
- variantARAF S214Ccivic_curation1.00
- variantARAF S214Fcivic_curation1.00
- variantRAF1 S257Lcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24569458
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ARAF S214C3 | ||||||||
| Sorafenib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID17In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission. PMID 24569458 · Imielinski et al., 2014 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID40Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro. PMID 24569458 · Imielinski et al., 2014 · Open in CIViC | civic |
| Trametinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID41Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro. PMID 24569458 · Imielinski et al., 2014 · Open in CIViC | civic |
| RAF1 S257L1 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 4 | accepted | EID12991RAF1 p.S257L (and p.S259A) induced anchorage-independent growth and increased MEK/ERK phosphorylation in AALE and NIH-3T3 cells in a sorafenib- and trametinib-sensitive manner. Supporting data is foun… (full text at CIViC) PMID 24569458 · Imielinski et al., 2014 · Open in CIViC | civic |
| ARAF S214F1 | ||||||||
| (functional) | —UNRESOLVED | Functional | B | Supports Gain Of Function | 5 | accepted | EID12972Imielinski et al displays functional evidence (Figure 3A) showing the S214F variant causes increased colony formation and increased pMEK/MEK ratio. PMID 24569458 · Imielinski et al., 2014 · Open in CIViC | civic |